EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Conditional cancer-specific survival in breast cancer with de novo bone metastases: A SEER-based study

Shilong Wang, Long Jia

Biomolecules and Biomedicine · 2026-09-30

DOI: 10.17305/bb.2026.14614 ↗
AbstractBibliografische Angaben

Abstract

Baseline survival estimates do not capture evolving prognosis in breast cancer with de novo bone metastases. We aimed to develop and internally evaluate a prognostic framework integrating baseline and conditional cancer-specific survival (CSS) estimates. Using the Surveillance, Epidemiology, and End Results (SEER) database, we retrospectively analysed 4,013 women diagnosed in 2010–2015 and randomly allocated 70% to training and 30% to internal validation. Random survival forest-assisted variable selection and Cox proportional hazards regression were used to construct baseline and conditional survival nomograms. Seven predictors were retained: age, primary tumour surgery, nodal stage, molecular subtype, and concomitant brain, liver, and lung metastases. The validation concordance index was 0.662 (95% confidence interval: 0.642–0.681), indicating moderate discrimination. Model-averaged probabilities of surviving to 10 years conditional on 5-year survival were 43.0% and 43.7% in training and validation, respectively, compared with unconditional CSS estimates of 17.2% and 17.7%. Landmark calibration was satisfactory for predicting subsequent 3-year CSS among 3-year survivors; other conditional scenarios were not empirically validated. The framework may support updated prognostic assessment once initial treatment status is known. However, 10-year estimates remain exploratory because of limited late follow-up and non-proportional hazards, and external validation is needed before clinical application.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →